USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
The burden of treating chronic wounds is growing rapidly due to increasing health care costs
Gafchromic films support patient care in oncology
Roflumilast reduces inflammation in the lungs that leads to chronic obstructive pulmonary disease (COPD)
Several late-stage pipeline products have the potential to address some of these unmet needs
Everest and SPH Kyuan will work closely to promote import and channel distribution of XERAVA in China
Digitization has unleashed a flood of data that presents a huge opportunity but is also overwhelming clinicians, nurses, and administrators
The data highlight the three drug candidates' potential for clinical development and promising synergistic utilities in new indications
WuXi Bio provided technical services, based on the companies' versatile integrated service platforms, to support various manufacturing and process development activities of these ADC product candidates.
The blood test market worldwide is today around $75-80 billion
Subscribe To Our Newsletter & Stay Updated